Yellapantula, Venkata
Hultcrantz, Malin http://orcid.org/0000-0002-9045-6495
Rustad, Even H. http://orcid.org/0000-0002-9320-4963
Wasserman, Ester
Londono, Dory
Cimera, Robert
Ciardiello, Amanda
Landau, Heather
Akhlaghi, Theresia
Mailankody, Sham
Patel, Minal
Medina-Martinez, Juan Santiago http://orcid.org/0000-0001-8444-153X
Arango Ossa, Juan Esteban
Levine, Max Fine
Bolli, Niccolo
Maura, Francesco
Dogan, Ahmet http://orcid.org/0000-0001-6576-5256
Papaemmanuil, Elli
Zhang, Yanming
Landgren, Ola http://orcid.org/0000-0001-6485-4839
Article History
Received: 30 August 2019
Revised: 31 October 2019
Accepted: 15 November 2019
First Online: 11 December 2019
Change Date: 30 January 2020
Change Type: Correction
Change Details: A correction to this paper has been published and can be accessed via a link at the top of the paper.
Conflict of interest
: M.H. has received funding from the Multiple Myeloma Research Foundation, the Swedish Research Council, the Swedish Cancer Society, Karolinska Institute Foundations, and the Swedish Blood Cancer Foundation. N.B. has received Honoraria/ad boards from: Celgene, Janssen, Novartis. E.H. is a Josie Robertson Investigator, an EHA Fellow, and an ASH Scholar. O.L. has received research funding from: National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), Multiple Myeloma Research Foundation (MMRF), International Myeloma Foundation (IMF), Leukemia and Lymphoma Society (LLS), Perelman Family Foundation, Rising Tides Foundation, Amgen, Celgene, Janssen, Takeda, Glenmark, Seattle Genetics, Karyopharm; Honoraria/ad boards: Adaptive, Amgen, Binding Site, BMS, Celgene, Cellectis, Glenmark, Janssen, Juno, Pfizer; and serves on Independent Data Monitoring Committees (IDMCs) for clinical trials lead by Takeda, Merck, Janssen, and Theradex. There is a pending patent application regarding the myTYPE assay (M.H., E.P., and O.L.). The remaining authors declare no relevant conflicts of interest.